Medical device rules eased for outsourced sterilisation; EU added to stringent regulatory jurisdictions
2-minute summary
The Union Health Ministry has proposed key amendments to the Medical Devices Rules, 2017, to enhance the ease of doing business and accelerate market access for medical technologies. Under the amendment to Rule 44, manufacturers outsourcing sterilisation to licensed third-party facilities are exempted from obtaining a separate loan licence, reducing administrative overhead while maintaining safety through mandatory label traceability. Additionally, the amendment to Rule 63 includes the European Union (EU) in the list of recognized stringent regulatory jurisdictions (joining the US, UK, Australia, Canada, and Japan). This inclusion allows for the waiver of local clinical investigation requirements for eligible medical devices that lack predicate devices in India, ensuring faster availability of advanced medical technologies. These reforms balance regulatory oversight with simplified compliance, fostering international regulatory convergence and strengthening India's medical device ecosystem.
Why it's in the news
The Union Ministry of Health and Family Welfare has proposed significant amendments to the Medical Devices Rules, 2017. These changes aim to simplify licensing for outsourced sterilisation and expand the list of recognized global regulatory jurisdictions to include the European Union, facilitating faster domestic approvals.
Background and context
India's medical devices sector is a vital component of the healthcare industry, historically dependent on imports for nearly 70-80% of its requirements. To regulate this sector systematically, the government notified the Medical Devices Rules, 2017, under the Drugs and Cosmetics Act, 1940. These rules classified medical devices into four risk-based categories (Class A, B, C, and D). While the regulatory framework ensured safety, manufacturers frequently faced compliance bottlenecks, such as dual-licensing for outsourced processes like sterilisation and mandatory local clinical trials for advanced devices lacking Indian predicates. The 2026 amendments address these pain points by streamlining licensing and recognizing global regulatory standards, aligning India with international best practices and supporting the National Medical Devices Policy's goal of making India a global manufacturing hub.
Constitutional provisions
- Article 47 — Directs the State to regard the raising of the level of nutrition and the standard of living of its people and the improvement of public health as among its primary duties.
Committees and reports
- 138th Report of the Parliamentary Standing Committee on Health and Family Welfare on 'Medical Devices: Regulation and Control' — Recommended streamlining the regulatory pathway, reducing compliance burdens, and promoting domestic manufacturing of medical devices.
Government schemes
- National Medical Devices Policy, 2023 — Aims to facilitate orderly growth of the medical device sector, meet public health objectives, and foster ease of doing business.
- Production Linked Incentive (PLI) Scheme for Medical Devices — Encourages domestic manufacturing and attracts large investments in the medical devices sector.
International organisations
- European Medicines Agency (EMA) / European Union Regulatory Framework — The EU has been added to India's list of stringent regulatory jurisdictions, enabling clinical trial waivers for EU-approved medical devices.
Mains practice: Analyze how the recent amendments to the Medical Devices Rules, 2017, balance the twin objectives of 'Ease of Doing Business' and 'Patient Safety' in India's healthcare sector.
The recent amendments proposed by the Union Health Ministry to the Medical Devices Rules, 2017, mark a significant shift towards regulatory agility, balancing the promotion of domestic manufacturing with public safety.
• **Promoting Ease of Doing Business and Reducing Compliance Costs**:
Under the amended Rule 44, manufacturers outsourcing sterilisation to licensed facilities no longer require a separate duplicate 'loan licence'. This eliminates redundant paperwork, administrative delays, and compliance costs, particularly benefiting Micro, Small, and Medium Enterprises (MSMEs) that rely on third-party infrastructure.
• **Accelerating Market Access and Global Convergence**:
By amending Rule 63 to include the European Union (EU) alongside the US, UK, Australia, Canada, and Japan as a recognized stringent regulatory jurisdiction, India has simplified the entry of advanced medical technologies. Eligible devices approved in the EU can now obtain clinical investigation waivers in India, significantly reducing regulatory timelines and ensuring Indian patients gain faster access to life-saving innovations.
• **Safeguarding Patient Safety and Traceability**:
Despite easing licensing requirements, the government has not compromised on safety. The amendment mandates that the licence number of the outsourced sterilisation facility must be clearly printed on the medical device label, ensuring robust traceability. Furthermore, a six-month transition period allows the industry to adapt packaging and labeling processes without disrupting supply chains.
In conclusion, these amendments successfully harmonize India's regulatory standards with global benchmarks. By reducing bureaucratic hurdles while maintaining strict traceability, the reforms support the National Medical Devices Policy's vision of fostering a competitive, safe, and self-reliant medical devices ecosystem.
Prelims practice questions
Q1. With reference to the recent amendments to the Medical Devices Rules, 2017, consider the following statements: 1. Manufacturers outsourcing sterilisation to a licensed facility are completely exempted from mentioning the sterilisation facility's details on the product label. 2. A transition period of six months has been provided to allow companies to modify labels and packaging. Which of the statements given above is/are correct?
- 1 only
- 2 only
- Both 1 and 2
- Neither 1 nor 2
Answer: B. Statement 1 is incorrect because traceability requirements have been retained; manufacturers must mention the licence number of the sterilisation facility on the medical device label. Statement 2 is correct as a six-month transition period is provided for companies to modify labels and packaging.
Q2. Under the amended Rule 63 of the Medical Devices Rules, 2017, which of the following jurisdictions is the latest addition to the list of stringent regulatory jurisdictions recognized for waiving clinical investigation requirements in India?
- Switzerland
- European Union
- South Korea
- Singapore
Answer: B. The amendment to Rule 63 includes the European Union (EU) among the stringent regulatory jurisdictions recognized for waiving clinical investigation requirements, joining the US, UK, Australia, Canada, and Japan.
Q3. The Medical Devices Rules, 2017, which govern the manufacture, import, and clinical investigation of medical devices in India, are framed under which of the following legislations?
- The Prevention of Food Adulteration Act, 1954
- The Drugs and Cosmetics Act, 1940
- The National Medical Commission Act, 2019
- The Bureau of Indian Standards Act, 2016
Answer: B. The Medical Devices Rules, 2017, are framed and regulated under the provisions of the Drugs and Cosmetics Act, 1940, and are administered by the Central Drugs Standard Control Organisation (CDSCO).
Revision flashcards
- What is the primary change introduced in Rule 44 of the Medical Devices Rules, 2017? It waives the requirement of a separate loan licence for manufacturers outsourcing sterilisation to a facility holding a valid licence.
- How is traceability maintained under the amended Rule 44 for outsourced sterilisation? Manufacturers must print the licence number of the outsourced sterilisation facility on the medical device label.
- Which new jurisdiction was added to Rule 63 for clinical investigation waivers of medical devices? The European Union (EU).
- Name the five jurisdictions previously recognized under Rule 63 before the EU's inclusion. United States (US), United Kingdom (UK), Australia, Canada, and Japan.
- What is the transition period allowed for companies to implement the new labeling changes under Rule 44 (as of August 2026)? A six-month transition period.